Brazil is widely recognized as the largest healthcare market in Latin America and one of the most promising destinations for global medical device manufacturers. With a complex regulatory framework and strong demand for innovative technologies, the country offers significant opportunities but also requires a structured approach to market entry.  One of the most effective strategies for international companies seeking to enter the Brazilian market is regulatory hosting, a model that enables manufacturers to operate locally without the need to establish a subsidiary or build a full regulatory and operational structure from scratch.  At Brisa, regulatory hosting is more than an administrative service. It is a strategic gateway that allows global manufacturers to access the Brazilian healthcare ecosystem with agility, compliance, and commercial readiness.  Understanding Regulatory Hosting in Brazil  In Brazil, medical devices must be registered or notified with the national regulatory authority, the Agência Nacional de Vigilância Sanitária (ANVISA). To complete this process, foreign manufacturers must appoint a Brazilian Registration Holder (BRH), a locally established entity legally responsible for the product registration and its compliance with Brazilian regulations.  Regulatory hosting is the model through which a qualified Brazilian partner assumes this role on behalf of the manufacturer. This structure allows international companies to:  However, the effectiveness of this model depends heavily on the quality, governance, and strategic vision of the hosting partner.  Beyond Compliance: The Strategic Value of Regulatory Hosting  While regulatory hosting is often perceived as a legal requirement, in practice it can become a powerful business accelerator when managed strategically. A specialized partner can help manufacturers:  The Brisa Model: Regulatory Hosting Within an Integrated Ecosystem  What differentiates Brisa is that regulatory hosting is not offered in isolation. Instead, it is part of an integrated ecosystem that connects regulatory strategy, market access, purchasing networks, and distribution capabilities. This model enables manufacturers to move seamlessly from regulatory approval to commercial execution.  Within the Brisa ecosystem, regulatory hosting connects directly with:  This integrated approach reduces fragmentation and eliminates the need to coordinate multiple independent partners across the regulatory and commercial journey. For global manufacturers, the result is a simpler, faster, and more secure entry into the Brazilian healthcare market.  A Strategic Bridge Between Innovation and Market Access  Brazil’s healthcare system continues to evolve rapidly, driven by technological innovation, demographic shifts, and increasing demand for advanced medical solutions. In this environment, regulatory hosting becomes more than a compliance mechanism; it becomes a strategic bridge between global innovation and local healthcare delivery.  By combining regulatory expertise with operational and commercial capabilities, Brisa helps manufacturers transform regulatory approval into real market presence. Because entering a new market should not be defined by complexity, but by opportunity.  Find out more about BPO in RA!   *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br  

When Time Equals Value: How Efficient Regulation Drives Innovation and Growth  In healthcare, every regulatory decision carries economic weight. From the moment a medical device begins its approval process to the point it reaches the market, time, cost, and opportunity are inseparably linked. Efficient regulatory systems not only protect patients but they also stimulate innovation, attract investment, and strengthen competitiveness.  At Brisa, we see regulatory efficiency as both a public health priority and a strategic economic driver for the medical device industry.  1. The Economics of Time to Market  For medical device manufacturers, time to market is one of the most critical business metrics. Every month of delay in regulatory approval can mean postponed revenue, missed hospital procurement cycles, and delayed access for patients. Studies show that reducing approval timelines while maintaining quality and safety directly translates into:  Faster return on investment (ROI);  Lower operational costs;  Earlier feedback from real-world use;  Stronger reinvestment capacity for R&D.  In emerging markets like Brazil, where healthcare demand is growing rapidly, shortening this journey without compromising rigor creates a win-win scenario for companies, regulators, and patients alike.  2. Regulation as an Economic Enabler  Regulation is often viewed as a cost center but when well-structured, it becomes a growth catalyst. By providing predictability, transparency, and risk-based oversight, regulatory efficiency enables companies to plan and invest with confidence. Efficient frameworks also improve national competitiveness.  Countries that streamline regulatory processes tend to:  Attract more foreign manufacturers seeking stable market conditions;  Stimulate local innovation by reducing administrative barriers;  Enhance public health outcomes, which in turn drive productivity and social development.  In this sense, regulatory efficiency is not just good governance; it is economic strategy.  3. The Brazilian Context: Progress Through Modernization  Over the past decade, Anvisa has made significant progress toward modernization. Initiatives such as digital submissions, harmonization with the International Medical Device Regulators Forum, and risk-based evaluations have increased transparency and reduced bureaucracy.  Resolutions like RDC 751/2022 which redefined the classification and registration of medical devices are evidence of this evolution. These reforms have improved alignment with international standards while maintaining Brazil’s high level of regulatory rigor. The result is faster approvals, stronger oversight, and a growing reputation for regulatory reliability in Latin America.  4. How Brisa Creates Economic Value Through Regulatory Strategy  At Brisa, we help manufacturers capture the full economic potential of efficient regulation. Our integrated ecosystem combines technical expertise, data-driven analysis, and operational agility to reduce delays, avoid rework, and optimize cost across the entire regulatory lifecycle.  We support our clients by:  Designing efficient registration strategies based on product risk and market goals;  Anticipating and adapting to Anvisa’s evolving requirements;  Streamlining documentation and technical justification;  Managing renewals, post-market surveillance, and quality compliance.  By aligning compliance with business priorities, Brisa turns regulatory management into a strategic investment: one that drives growth rather than restricts it.  5. The Multiplier Effect of Efficiency  Regulatory efficiency produces a ripple effect across the entire healthcare ecosystem:  Manufacturers gain faster access and reduced costs;  Distributors benefit from predictability and portfolio expansion;  Healthcare providers access new technologies sooner;  Patients receive safer, more advanced care faster;  Regulators strengthen oversight through clearer data and governance.  In the long term, this synergy supports a more competitive, innovative, and sustainable healthcare market.  6. Conclusion: Efficiency as a Shared Responsibility  Regulatory efficiency is not achieved by speed alone; it is about balance. It requires collaboration between regulators, industry, and consulting partners who share the same purpose: ensuring safety while enabling innovation.  At Brisa, we believe that when regulation works efficiently, everyone benefits from global manufacturers to local healthcare systems and, ultimately, to the patients whose lives depend on timely access to innovation. Because in healthcare, e  Find out more about BPO in RA!   *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br  

In the highly regulated world of healthcare, success depends not only on technical expertise, but on trust, transparency, and partnership.  Manufacturers, distributors, regulatory agencies, and consultants each play a critical role in ensuring that innovative medical technologies reach patients safely and efficiently. At Brisa, we believe that lasting success in the Brazilian healthcare market is built through long-term partnerships, not transactional relationships.  Our approach combines deep regulatory knowledge with a collaborative mindset, turning compliance into connection and complexity into opportunity.  1. The Importance of Collaboration in Healthcare  The healthcare value chain is increasingly interconnected.  A single medical device’s journey involves dozens of stakeholders, from engineers and clinical evaluators to importers, regulators, and end users. Without collaboration, that chain becomes fragmented. With collaboration, it becomes a living ecosystem, capable of adapting, sharing knowledge, and creating collective value.  For international manufacturers entering Brazil, collaboration with the right local partner is the difference between market entry and market success. A strong partnership ensures alignment across regulatory, logistical, and commercial fronts, resulting in faster access, reduced risk, and higher trust among all players involved.  2. Partnership as a Strategic Advantage  In a sector defined by regulatory rigor and constant evolution, long-term partnerships provide stability. They create a framework for shared learning, joint problem-solving, and continuous improvement.  At Brisa, we act as more than a regulatory consultant. We become an extension of our clients’ teams, helping them make informed decisions, anticipate regulatory changes, and build strategies for sustainable growth. This long-term vision enables manufacturers to focus on innovation, while Brisa ensures that every step, from registration to distribution, operates smoothly and in full compliance.  3. The Brisa Ecosystem: Connecting Expertise and Execution  Our integrated model is designed to unite all aspects of market access under one collaborative structure. Within the Brisa ecosystem, we combine:  Regulatory consulting, ensuring compliance with Anvisa and international standards.  Legal representation, acting as a trusted partner for foreign manufacturers.  Importation and logistics, optimizing cost, timing, and tax efficiency.  Strategic distribution networks, linking products to healthcare providers and buyers across Brazil.  This ecosystem allows information to flow transparently between stakeholders, eliminating silos and ensuring that innovation moves seamlessly from concept to clinic.  4. Trust and Transparency: The Foundation of Every Partnership  Every partnership we build at Brisa is rooted in trust and transparency. Our clients have full visibility of their regulatory and operational processes, supported by clear governance and open communication.  We believe that trust is not declared; it’s demonstrated. It’s built through consistent delivery, reliability, and the ability to transform challenges into measurable results. That’s why many of our international clients see Brisa not only as a service provider but as a strategic ally, one that understands their goals and shares their commitment to excellence.  5. From Partnership to Shared Growth  True partnership goes beyond contracts. It means growing together, adapting together, and learning from each success and challenge.  In healthcare, where innovation evolves faster than regulation, shared growth ensures agility. It allows companies and consultants to co-create strategies that anticipate change rather than react to it. At Brisa, we’re proud to have built long-standing relationships based on mutual respect and a shared mission: to connect global innovation with Brazilian healthcare needs, responsibly and sustainably.  6. Conclusion: Collaboration as the Future of Healthcare  The future of healthcare will be collaborative. As technologies become more complex and global, no single organization can succeed in isolation.  At Brisa, our approach is simple but powerful: partnership over transaction, collaboration over competition, and trust over convenience. Because when we work together, across borders, disciplines, and systems, innovation moves faster, access becomes broader, and patient outcomes improve.  That’s the Brisa way: partnership with purpose.  Find out more about BPO in RA!   *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br  

Brazil’s healthcare sector is entering a new era, one defined by digital transformation, medical technology, and intelligent systems that are reshaping the way care is delivered. From remote monitoring to surgical robotics and AI-driven diagnostics, innovation is no longer an abstract concept; it’s a daily reality in hospitals, clinics, and homes across the country. But innovation in healthcare can only thrive when it’s supported by robust regulation. That’s where the balance lies: enabling technological progress while protecting patients and ensuring safety, quality, and trust. At Brisa, we believe that regulation and innovation are not opposites, they are partners in progress. 1. A Market Ready for Innovation Brazil stands out as Latin America’s largest and most dynamic medical device market. With a population of over 200 million and one of the world’s most extensive public healthcare systems (SUS), the country presents both scale and diversity for new technologies. The growing demand for advanced diagnostics, connected care, and minimally invasive treatments is pushing hospitals and clinics to adopt smarter, data-driven solutions. At the same time, Anvisa’s modernization and alignment with international standards have created a more predictable environment for technology adoption. This combination of market demand plus regulatory maturity has turned Brazil into one of the most promising frontiers for medtech innovation. 2. Emerging Technologies Reshaping Care Some of the most transformative technologies now entering Brazil include: Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

The Brazilian Health Regulatory Agency ANVISA has issued Normative Instruction No. 426, dated February 13, 2026, establishing the requirements for data submission and management within the Unique Device Identification System SIUD. This regulation complements RDC No. 591/2021, strengthening the framework for medical device traceability in Brazil.  Key highlights of IN ANVISA 426/2026:  Why it matters: The publication of IN 426/2026 marks a milestone in the implementation of Brazil’s UDI system, aligning the country with international best practices in medical device traceability. The regulation enhances patient safety, strengthens post-market surveillance, improves regulatory processes, and increases the global competitiveness of the Brazilian medical device industry.  In summary, this normative instruction brings regulatory predictability, promotes data transparency, and reinforces the integration of all stakeholders in Brazil’s medical device ecosystem  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

The healthcare industry is experiencing a data revolution and regulatory affairs are no exception. In a sector defined by complexity, precision, and constant change, data and analytics have become essential tools for making faster, more accurate, and more strategic decisions.  For medical device manufacturers and distributors, the ability to analyze regulatory trends, performance indicators, and compliance metrics is now a key competitive differentiator. At Brisa, we see data not just as information, but as intelligence that guides the future of regulatory strategy.  1. Why Data Matters in Regulatory Affairs  Every regulatory process generates vast amounts of data, from dossier submissions and clinical evaluations to post-market reports and inspection records. Traditionally, this information has been handled manually, stored in silos, and used reactively.  Modern data analytics transforms that reality by allowing companies to:  This shift moves regulatory management from an operational task to a strategic intelligence function, where decisions are supported by objective evidence rather than assumptions.  2. Predictive Intelligence: Anticipating Change  Regulatory environments, particularly in Brazil, evolve continuously. Anvisa’s updates, new RDCs, and shifts in international harmonization policies can impact manufacturers’ market access strategies.  Through predictive analytics, companies can anticipate these movements by:  This approach allows organizations to stay ahead of change, adapt documentation proactively, and maintain a state of readiness, a crucial advantage in markets where time-to-approval directly affects competitiveness.  3. Data-Driven Post-Market Surveillance  After a product is approved, continuous monitoring becomes the next challenge. Data-driven post-market surveillance enables companies to detect safety signals, analyze field performance, and manage adverse event reports efficiently and transparently.  Brisa supports clients in establishing integrated systems that connect regulatory records, logistics data, and customer feedback. This integration ensures compliance with Anvisa’s vigilance requirements while reinforcing the manufacturer’s commitment to product quality and patient safety.  4. The Brisa Approach: Intelligence at the Core of Compliance  At Brisa, we combine regulatory expertise with data intelligence to transform compliance into a strategic advantage. Our approach integrates analytics into every stage of the regulatory journey:  This holistic model gives our clients full visibility and control over their regulatory operations, enabling smarter, faster, and more confident decision-making.  5. Conclusion: From Data to Strategy  The future of regulatory affairs belongs to organizations that turn data into foresight. In a world where information is abundant but time is limited, analytics provides the clarity needed to make decisions that are both compliant and competitive.  At Brisa, we believe that the true power of data lies in transforming regulatory management into strategic intelligence, bridging the gap between compliance and innovation.  Because in modern healthcare, insight is the new advantage.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

Entering the Brazilian healthcare market represents a powerful opportunity, but also a unique challenge. As one of the largest and most regulated medical device markets in the world, Brazil combines high growth potential with a complex regulatory, fiscal, and logistical environment.  For global manufacturers, the difference between success and delay often lies in finding a local partner who understands not only Anvisa’s regulatory framework, but also the commercial and operational realities of doing business in Brazil.  At Brisa, we bridge that gap. Through an integrated and strategic approach, we help international manufacturers move from regulatory approval to full market access: safely, efficiently, and with total transparency.  1. Understanding the Brazilian Landscape  Brazil accounts for nearly 40% of Latin America’s medical device market, making it an essential destination for manufacturers seeking regional expansion. However, its complexity (with a detailed regulatory process, layered taxation, and regionalized distribution) demands a structured and localized strategy.  Every successful market entry in Brazil depends on four pillars:  Brisa’s integrated ecosystem was designed to unify these pillars under one structure, minimizing risks and maximizing predictability.  2. Regulatory Consulting: Building a Strong Foundation  Regulation is the foundation of any market entry strategy. Our team of specialists provides comprehensive regulatory consulting, guiding clients through every step of the Anvisa process: from product classification and dossier preparation to registration and post-market obligations.  We also help manufacturers anticipate changes by monitoring regulatory updates and aligning their documentation with Anvisa’s evolving requirements. This proactive approach reduces approval timelines and strengthens long-term compliance.  3. Legal Representation: Acting as Your Trusted Partner in Brazil  For foreign manufacturers, it is mandatory to have a legal representative established in Brazil, an entity responsible for interacting with Anvisa and ensuring ongoing compliance. At Brisa, we assume this role with full accountability, managing the manufacturer’s regulatory portfolio and guaranteeing alignment with all local obligations.  Our governance model ensures transparency in every process, providing clients with real-time visibility of documentation, renewals, and regulatory milestones.  By acting as both representative and strategic advisor, we enable manufacturers to operate confidently in the Brazilian market.  4. Importation and Logistics: Turning Strategy into Operation  Once the product is approved, success depends on how efficiently it reaches the market. Brazil’s tax and customs landscape can be intricate, involving multiple authorities and state-level regulations.  Brisa manages the entire importation and logistics process, combining fiscal planning, warehousing, and distribution oversight to ensure compliance and efficiency.   We integrate regulatory and operational data into a single system, enabling faster clearance, accurate tracking, and full traceability.  This approach transforms potential bottlenecks into competitive advantages.  5. Commercial Integration: Connecting Innovation to the Market  Our role does not end with importation; we help manufacturers connect with the healthcare ecosystem. Through our strategic distribution network, Brisa facilitates market reach, connecting products with private hospitals, purchasing groups, and institutional buyers.  By aligning regulatory compliance with commercial execution, we help ensure that innovation not only enters the country but also reaches the patients who need it most.  6. Conclusion: From Entry to Expansion  Market entry into Brazil is a journey that demands expertise, foresight, and partnership. At Brisa, we combine all three.  By integrating regulatory consulting, legal representation, importation, and distribution under one ecosystem, we simplify the path for global manufacturers, transforming complexity into clarity and approval into access.  Because in Brazil, success belongs to those who understand that market access is more than registration: it’s strategy.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

In the medical device sector, regulatory approval is a major milestone, but it’s far from the final destination.  Obtaining registration from Anvisa validates a product’s safety and efficacy, but transforming that approval into real, sustainable market access in Brazil requires a much broader set of strategic, operational, and commercial actions.  The real challenge lies in integrating regulation, logistics, taxation, distribution, and governance into a single cohesive structure; something that has traditionally been fragmented across the healthcare industry.  At Brisa, we believe true innovation happens only when technology reaches the patient. And that requires a market access journey designed to be complete, predictable, and collaborative.  1. Approval Is the Beginning, Not the End  Anvisa registration marks the start of a complex journey involving multiple authorities, partners, and operational layers.  It ensures the product’s compliance with safety and quality standards, but it does not automatically guarantee commercialization or adoption within the Brazilian healthcare system.  Between approval and clinical use, several critical steps must occur:  When these stages are handled separately, companies face rework, delays, and additional costs.  But when managed strategically and in coordination, they become a source of efficiency and competitive advantage.  2. Turning Regulation into Access  Anvisa is internationally recognized for its technical rigor and maturity, positioning Brazil as a reference in Latin American regulatory systems. However, this same rigor demands a strategic understanding of the regulatory framework, one that looks beyond documentation to operational and commercial implications.  Market access requires connecting regulation to broader factors, such as:  Without this integrated perspective, many international manufacturers achieve registration but struggle to enter or sustain operations in the Brazilian market due to tax complexity, lack of local partners, or unpredictable import flows.  3. Market Access Strategy: The Bridge Between Regulation and Commerce  In healthcare, Market Access is much more than a regulatory step. It’s a coordinated process that aligns technical, economic, and strategic factors to ensure that products not only get approved but also reach the Brazilian healthcare system sustainably and at scale.  Its key pillars include:  When built strategically, market access transforms regulatory compliance into a growth roadmap, reducing risks and increasing predictability.  4. The Brisa Model: Integration as a Competitive Advantage  The Brisa ecosystem was designed to bridge the gap between regulation and market entry. Our integrated model unites all stages of the value chain, from regulatory consulting to commercialization, within a single, transparent, and traceable framework.  This means that international manufacturers gain a local partner capable of managing:  This model ensures efficiency, governance, and cost reduction, while providing predictability for international investors and decision-makers.  The result is a faster, safer, and more competitive pathway into Brazil: a true strategic gateway to the Latin American market.  5. Conclusion: Real Market Access Begins Where Regulation Ends  Regulation is essential, but the real impact of healthcare innovation happens when it reaches professionals and patients.  To achieve this, companies must view regulation as the foundation of a broader process that combines planning, governance, and collaboration.  At Brisa, we transform regulation into a pathway instead of a barrier. Our mission is to turn complexity into predictability, aligning technical compliance with strategic execution and ensuring that innovation completes its journey to where it matters most: improving lives.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

The healthcare industry is undergoing one of the most significant transformations in its history. Digitalization, artificial intelligence, and data-driven decision-making are redefining how medical technologies are developed, approved, and monitored.  In this new landscape, regulatory consulting is no longer limited to managing submissions and compliance, it has become a strategic function that shapes how innovation reaches patients. The future belongs to consultancies that can connect technical expertise, business intelligence, and digital agility.  From Reactive Compliance to Predictive Strategy  Traditional regulatory consulting focused primarily on reacting to updates and managing documentation. The new era demands something more: anticipation.  Consultancies must now interpret regulatory trends, anticipate future requirements, and design strategies that align compliance with business growth. This approach transforms regulation into a predictive advantage, allowing manufacturers and distributors to prepare for changes before they happen.  At Brisa, this shift is already part of our DNA. Through continuous monitoring of regulatory updates and data analytics, we provide our clients with insights that shape long-term decisions, not just immediate approvals.  Technology as an Enabler  The future of regulatory consulting will be powered by technology and automation. Digital platforms are already transforming how submissions, quality documentation, and post-market data are managed. Artificial Intelligence (AI) is enabling faster classification, error detection, and real-time monitoring of compliance indicators.  However, technology alone is not the differentiator, how it is applied strategically is what sets leaders apart.  At Brisa, we combine AI-driven tools with human expertise, ensuring that every insight is interpreted within the right regulatory and business context. This balance of technology and judgment creates efficiency without losing precision.  Global Convergence and the Rise of Cross-Border Expertise  As regulatory frameworks around the world become increasingly harmonized, manufacturers seek partners capable of operating across multiple markets. The modern consultancy must understand not only local regulations, like those of Anvisa, but also the broader network of standards from the IMDRF, FDA, and EMA.  For Brisa, this global perspective is essential. We work with international manufacturers who view Brazil not only as a market, but as a strategic hub for Latin America, a region that values both technical rigor and partnership-based collaboration.  By bridging local expertise with global requirements, Brisa provides clients with a unified regulatory strategy that scales.  Human Expertise Remains at the Core  Even as automation grows, human expertise remains irreplaceable. The ability to interpret gray areas, communicate effectively with regulators, and design creative yet compliant solutions is still rooted in human insight and experience.  At Brisa, our consultants combine years of technical knowledge with a deep understanding of how regulation interacts with business models. This is what allows us to move beyond process execution and into strategic guidance.  Conclusion: The Consultancy of the Future  The regulatory consultancy of the future will not just ensure compliance, it will shape markets, accelerate innovation, and enable access to healthcare technologies.  At Brisa, we are building this future today. By integrating intelligence, technology, and human expertise, we turn regulatory complexity into strategic clarity.  Because the future of consulting is not about managing regulations, it’s about leading through them.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br 

In the medical device industry, trust is the foundation of every business relationship between regulators, manufacturers, healthcare providers, and ultimately, patients.  That trust is built through compliance and ethical conduct, two pillars that ensure safety, transparency, and credibility in an increasingly complex regulatory environment.  At Brisa, compliance is not just a procedural requirement; it is part of our identity and a cornerstone of how we operate across every stage of the regulatory and commercial journey.  The Meaning of Compliance in the Regulatory Context  Compliance goes beyond following rules  it represents a commitment to integrity and responsibility.  In the context of medical devices, compliance encompasses a broad range of obligations, including:  * Regulatory adherence: meeting all requirements established by Anvisa and international health authorities.  * Quality management: maintaining certified systems, such as ISO 13485 and Good Manufacturing Practices (CBPF).  * Traceability and documentation: ensuring that every product, process, and transaction can be verified transparently.  * Corporate governance: adopting policies that align with ethical standards and prevent conflicts of interest.  By embedding these principles into daily operations, companies demonstrate respect for both regulation and the people it protects.  Ethics as a Strategic Value  Ethics in healthcare regulation is more than compliance — it is about decision-making guided by values.  In a sector that directly affects human lives, ethical choices are essential to ensure that commercial objectives never override patient safety.  An ethical approach means:  * Communicating transparently with regulators and partners.  * Managing data, approvals, and reporting with honesty and accountability.  * Ensuring that all market practices are fair, traceable, and aligned with the public interest.  * At Brisa, ethics defines how we represent our clients, manage partnerships, and deliver value.  We believe that sustainable business growth comes only from integrity and long-term trust.  The Relationship Between Compliance, Risk, and Reputation  A strong compliance structure not only prevents penalties or delays  it protects corporate reputation and market longevity.  In the medical device industry, noncompliance can lead to product recalls, import suspensions, and reputational damage that takes years to rebuild.  Conversely, companies with mature compliance programs gain a competitive advantage:  – Faster approvals due to reliable documentation and transparency.  – Stronger relationships with regulators.  – Greater confidence from partners and healthcare institutions.  In a market increasingly guided by data and digital governance, integrity has become a measurable asset.  Brisa’s Commitment to Ethical Compliance  At Brisa, compliance is embedded into every process of our integrated ecosystem.  We maintain transparent workflows, continuous monitoring of regulatory updates, and rigorous internal governance to ensure that our operations  and those of our clients meet the highest ethical standards.  Our role is to connect global innovation to the Brazilian market responsibly, ensuring that every product reaching patients has passed through a chain of integrity and trust.  Conclusion: Ethics as the Future of Regulation  As healthcare regulation evolves, ethics and compliance are not just expectations — they are strategic imperatives.  They build the credibility that sustains innovation and the partnerships that make global collaboration possible.  At Brisa, we believe that compliance is not the end of the regulatory process  it is the beginning of a relationship built on trust, transparency, and purpose.  Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br    Find out more about BPO in RA!  *Budget for registration ownership transfer, Market Access Strategy, and BPO in RA services for your company: www.brisa.com.br